From Ganfyd

Jump to: navigation, search

Ruboxistaurin mesylate (LY333531) is a bisindolylmaleimide inhibitor of a PKC isoform - protein kinase C beta(PKC-β). Its development to prevent complications in type 2 diabetes was halted during phase III trials in diabetic retinopathy due some unfavourable primary end point data on retinopathy progression[1] even though it may have reduced visual loss[2].